When you put them together, trading success is nearly inevitable.
You can't call this market overbought when so much of it isn't participating.
Trading in biotech stocks and a particular SPAC play are on my mind.
Income investors should find the yield attractive, which is double that of the average yield of the S&P 500 index.
The S&P 500's valuation continues to be extended.
Bids from Western venture capital investors for age-old Japanese names are only likely to increase.
Keep this one on the ready for entry Friday for a swing trade.
I don't think President Biden pays much attention to the stock market at all.
The stock is trading near its recent secondary pricing and has very attractive price targets from analysts.
The issue is when the data conflict with the prevailing narrative. We are in such a position now.